E Fund Management Co. Ltd. Buys Shares of 10,385 Arbutus Biopharma Co. (NASDAQ:ABUS)

E Fund Management Co. Ltd. purchased a new position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 10,385 shares of the biopharmaceutical company’s stock, valued at approximately $34,000.

A number of other institutional investors and hedge funds have also modified their holdings of ABUS. Raymond James Financial Inc. acquired a new position in Arbutus Biopharma during the fourth quarter worth $34,000. Charles Schwab Investment Management Inc. raised its stake in shares of Arbutus Biopharma by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,222,201 shares of the biopharmaceutical company’s stock worth $3,997,000 after buying an additional 9,955 shares during the last quarter. SBI Securities Co. Ltd. purchased a new stake in shares of Arbutus Biopharma in the 4th quarter worth about $236,000. Rhumbline Advisers grew its stake in Arbutus Biopharma by 6.0% in the 4th quarter. Rhumbline Advisers now owns 188,598 shares of the biopharmaceutical company’s stock valued at $617,000 after acquiring an additional 10,724 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in Arbutus Biopharma by 10.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 40,179 shares of the biopharmaceutical company’s stock valued at $131,000 after acquiring an additional 3,870 shares during the last quarter. Institutional investors and hedge funds own 43.79% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Arbutus Biopharma in a report on Tuesday, January 21st. StockNews.com upgraded Arbutus Biopharma from a “sell” rating to a “hold” rating in a research report on Wednesday, March 5th. Finally, Chardan Capital reiterated a “buy” rating and set a $5.00 target price (up previously from $4.50) on shares of Arbutus Biopharma in a report on Wednesday, November 20th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $5.50.

Arbutus Biopharma Price Performance

Shares of NASDAQ ABUS opened at $3.31 on Monday. The company has a market cap of $627.22 million, a PE ratio of -7.70 and a beta of 1.93. The company has a 50-day simple moving average of $3.34 and a 200-day simple moving average of $3.64. Arbutus Biopharma Co. has a 12 month low of $2.30 and a 12 month high of $4.73.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.